Top

Published in:

01-11-2011 | Original Article

Matrix metalloproteinase 13 in the ligamentum flavum from lumbar spinal canal stenosis patients with and without diabetes mellitus

Authors: Guanyu Cui, Kota Watanabe, Yoshiteru Miyauchi, Naobumi Hosogane, Takashi Tsuji, Ken Ishii, Masaya Nakamura, Yoshiaki Toyama, Kazuhiro Chiba, Takeshi Miyamoto, Morio Matsumoto

Published in: Journal of Orthopaedic Science | Issue 6/2011

Abstract

Background

Lumbar spinal canal stenosis (LSCS) is one of the most common spinal disorders in the elderly, and ligamentum flavum (LF) hypertrophy is an important cause of LSCS. Matrix metalloproteinase 13 (MMP13) can degrade fibrillar collagens and elastic microfibrils, and is involved in inflammation and fibrosis. The purpose of this study was to compare the expression of MMP13 in the LF from LSCS patients with diabetes mellitus [DM (+)] with that in the LF from patients without DM [DM (−)] and to analyze the relationship among DM, MMP13 expression, and LF hypertrophy.

Methods

LFs from 11 DM (+) and 24 DM (−) LSCS patients were analyzed in this study. Histology analysis using hematoxylin and eosin and Masson’s trichrome stain was performed for each LF. The expression of MMP13 was analyzed by quantitative real-time PCR. The thickness of LF was measured by CT.

Results

In the LF from DM (+) LSCS patients, the elastic fibers were more disorganized and had lower volumes than in the LF from DM (−) LSCS patients, while more fibrotic tissue was observed in the LF from DM (+) than from DM (−) LSCS patients. MMP13 expression was significantly higher in the LF from DM (+) LSCS patients (0.46 ± 0.61 vs. 0.05 ± 0.09, P = 0.002). The LF from the DM (+) LSCS patients was significantly thicker than that from the DM (−) LSCS patients (5.0 ± 0.9 vs. 3.1 ± 0.8 mm, P < 0.01), and the thickness was correlated with the expression of MMP13 (correlation coefficient = 0.43, P = 0.01, Pearson's correlation test).

Conclusion

DM-related MMP13 expression can be one of the factors contributing to fibrosis and hypertrophy of the LF. Further research on the mechanism of this process may lead to new therapies for LF hypertrophy.

Hansson T, Suzuki N, Hebelka H, Gaulitz A. The narrowing of the lumbar spinal canal during loaded MRI: the effects of the disc and ligamentum flavum. Eur Spine J. 2009;18:679–86.PubMedCrossRef

Nihei A, Hagiwara K, Kikuchi M, Yashiro T, Hoshino Y. Histological investigation of rabbit ligamentum flavum with special reference to differences in spinal levels. Anat Sci Int. 2003;78:162–7.PubMedCrossRef

Sairyo K, Biyani A, Goel V, Leaman D, Booth R Jr, Thomas J, Gehling D, Vishnubhotla L, Long R, Ebraheim N. Pathomechanism of ligamentum flavum hypertrophy: a multidisciplinary investigation based on clinical, biomechanical, histologic, and biologic assessments. Spine. 2005;30:2649–56.PubMedCrossRef

Okuda T, Baba I, Fujimoto Y, Tanaka N, Sumida T, Manabe H, Hayashi Y, Ochi M. The pathology of ligamentum flavum in degenerative lumbar disease. Spine. 2004;29:1689–97.PubMedCrossRef

Schrader PK, Grob D, Rahn BA, Cordey J, Dvorak J. Histology of the ligamentum flavum in patients with degenerative lumbar spinal stenosis. Eur Spine J. 1999;8:323–8.PubMedCrossRef

Postacchini F, Gumina S, Cinotti G, Perugia D, DeMartino C. Ligamenta flava in lumbar disc herniation and spinal stenosis: light and electron microscopic morphology. Spine. 1994;19:917–22.PubMedCrossRef

Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92:827–39.PubMedCrossRef

Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;274:21491–4.PubMedCrossRef

Oh IS, Ha KY. Matrix metalloproteinase-3 on ligamentum flavum in degenerative lumbar spondylolisthesis. Spine. 2009;34:E552–7.PubMedCrossRef

10.

Park JB, Lee JK, Park SJ, Riew KD. Hypertrophy of ligamentum flavum in lumbar spinal stenosis associated with increased proteinase inhibitor concentration. J Bone Joint Surg Am. 2005;87:2750–7.PubMedCrossRef

11.

Ashworth JL, Murphy G, Rock MJ, Sherratt MJ, Shapiro SD, Shuttleworth CA, Kielty CM. Fibrillin degradation by matrix metalloproteinases: implications for connective tissue remodeling. Biochem J. 1999;340(Pt 1):171–81.PubMedCrossRef

12.

Flechsig P, Hartenstein B, Teurich S, Dadrich M, Hauser K, Abdollahi A, Gröne HJ, Angel P, Huber PE. Loss of matrix metalloproteinase-13 attenuates murine radiation-induced pulmonary fibrosis. Int J Radiat Oncol Biol Phys. 2010;77:582–90.PubMedCrossRef

13.

Uchinami H, Seki E, Brenner DA, D’Armiento J. Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. Hepatology. 2006;44:420–9.PubMedCrossRef

14.

Tan RJ, Fattman CL, Niehouse LM, Tobolewski JM, Hanford LE, Li Q, Monzon FA, Parks WC, Oury TD. Matrix metalloproteinases promote inflammation and fibrosis in asbestos-induced lung injury in mice. Am J Respir Cell Mol Biol. 2006;35:289–97.PubMedCrossRef

15.

Park JB, Kong CG, Suhl KH, Chang ED, Riew KD. The increased expression of matrix metalloproteinases associated with elastin degradation and fibrosis of the ligamentum flavum in patients with lumbar spinal stenosis. Clin Orthop Sur. 2009;1:81–9.CrossRef

16.

Sachidanandam K, Hutchinson JR, Elgebaly MM, Mezzetti EM, Dorrance AM, Motamed K, Ergul A. Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1. Am J Physiol Regul Integr Comp Physiol. 2009;296:R952–9.PubMedCrossRef

17.

Takahashi H, Akiba K, Noguchi T, Ohmura T, Takahashi R, Ezure Y, Ohara K, Zieske JD. Matrix metalloproteinase activity is enhanced during corneal wound repair in high glucose condition. Curr Eye Res. 2000;21:608–15.PubMed

18.

Leeson CR, Leeson S, Paparo AA. In: Atlas of histology. 2nd ed. Philadelphia: Saunders; 1985. pp. 249–66.

19.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–8.PubMedCrossRef

20.

Fukuyama S, Nakamura T, Ikeda T, Takagi K. The effect of mechanical stress on hypertrophy of the lumbar ligamentum flavum. J Spinal Disord. 1995;8:126–30.PubMedCrossRef

21.

Tian XL, Yao W, Guo ZJ, Gu L, Zhu YJ. Low dose pirfenidone suppresses transforming growth factor beta-1 and tissue inhibitor of metalloproteinase-1, and protects rats from lung fibrosis induced by bleomycina. Chin Med Sci J. 2006;21:145–51.PubMed

22.

Asano Y, Ihn H, Kubo M, Jinnin M, Mimura Y, Ashida R, Tamaki K. Clinical significance of serum levels of matrix metalloproteinase-13 in patients with systemic sclerosis. Rheumatology (Oxford). 2006;45:303–7.CrossRef

Title: Matrix metalloproteinase 13 in the ligamentum flavum from lumbar spinal canal stenosis patients with and without diabetes mellitus
Authors: Guanyu Cui
Kota Watanabe
Yoshiteru Miyauchi
Naobumi Hosogane
Takashi Tsuji
Ken Ishii
Masaya Nakamura
Yoshiaki Toyama
Kazuhiro Chiba
Takeshi Miyamoto
Morio Matsumoto
Publication date: 01-11-2011
Publisher: Springer Japan
Published in: Journal of Orthopaedic Science / Issue 6/2011
Print ISSN: 0949-2658
Electronic ISSN: 1436-2023
DOI: https://doi.org/10.1007/s00776-011-0135-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Matrix metalloproteinase 13 in the ligamentum flavum from lumbar spinal canal stenosis patients with and without diabetes mellitus

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2011

A comparison of muscle strength testing for great toe extension

Ribbing disease (multiple diaphyseal sclerosis): a case report and literature review

A compound heterozygous mutation of CYP27A1 gene in a Taiwanese patient with cerebrotendinous xanthomatosis

Reliability and validity of the Western Ontario Shoulder Instability Index (WOSI) in the Japanese population

Severe septic arthritis of the shoulder with an axillary nerve lesion in a 4-year-old child

Medical problems and risk factors of metabolic syndrome among radiographic knee osteoarthritis patients in the Japanese general population